EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19

Writing Committee for the REMAP-CAP Investigators, Patrick R Lawler, Lennie P G Derde, Frank L van de Veerdonk, Bryan J McVerry, David T Huang, Lindsay R Berry, Elizabeth Lorenzi, Roland van Kimmenade, Frank Gommans, Muthiah Vaduganathan, David E Leaf und 48 weitere

JAMA · 2023

DOI: 10.1001/jama.2023.4480 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, 2023. Verfasst von Writing Committee for the REMAP-CAP Investigators und 59 weiteren Autor:innen. Beteiligte Einrichtung: Peter Munk Cardiac Centre at University Health Network, Toronto, Canada. Hauptthemen laut MEDLINE: Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors, COVID-19, Renin-Angiotensin System. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Research Council, Chief Scientist Office, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02735707

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsCOVID-19Renin-Angiotensin SystemCOVID-19 Drug TreatmentFemaleHumansMaleMiddle AgedBayes TheoremHospitalizationCritical IllnessReceptors, Chemokine

Substanzen

Angiotensin Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsReceptors, Chemokine

Autor:innen und Institutionen

  • Peter Munk Cardiac Centre at University Health Network, Toronto, Canada.
  • McGill University Health Centre, Montreal, QC, Canada.
  • University Medical Center Utrecht, Utrecht, Netherlands.
  • Radboud University Medical Centre, Nijmegen, Netherlands.
  • University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Berry Consultants, Austin, Texas.

Förderung

  • Medical Research Council
  • Chief Scientist Office
  • NIGMS NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Writing Committee for the REMAP-CAP Investigators, Lawler, P. R., Derde, L. P. G., van de Veerdonk, F. L., McVerry, B. J., Huang, D. T., Berry, L. R., Lorenzi, E., van Kimmenade, R., Gommans, F., Vaduganathan, M., Leaf, D. E., Baron, R. M., Kim, E. Y., Frankfurter, C., Epelman, S., Kwan, Y., Grieve, R., O'Neill, S., …, & Nichol, A. D. (2023). Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19. JAMA. https://doi.org/10.1001/jama.2023.4480

Vancouver

Writing Committee for the REMAP-CAP Investigators, Lawler PR, Derde LPG, van de Veerdonk FL, McVerry BJ, Huang DT, et al. Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19. JAMA. 2023. doi:10.1001/jama.2023.4480

BibTeX
@article{WritingCommitteefortheREMAPCAPInvestigators2023,
  author = {Writing Committee for the REMAP-CAP Investigators, Writing Committee for the REMAP-CAP Investigators and Lawler, Patrick R and Derde, Lennie P G and van de Veerdonk, Frank L and McVerry, Bryan J and Huang, David T and Berry, Lindsay R and Lorenzi, Elizabeth and van Kimmenade, Roland and Gommans, Frank and Vaduganathan, Muthiah and Leaf, David E and Baron, Rebecca M and Kim, Edy Y and Frankfurter, Claudia and Epelman, Slava and Kwan, Yvonne and Grieve, Richard and O'Neill, Stephen and Sadique, Zia and Puskarich, Michael and Marshall, John C and Higgins, Alisa M and Mouncey, Paul R and Rowan, Kathryn M and Al-Beidh, Farah and Annane, Djillali and Arabi, Yaseen M and Au, Carly and Beane, Abi and van Bentum-Puijk, Wilma and Bonten, Marc J M and Bradbury, Charlotte A and Brunkhorst, Frank M and Burrell, Aidan and Buzgau, Adrian and Buxton, Meredith and Cecconi, Maurizio and Cheng, Allen C and Cove, Matthew and Detry, Michelle A and Estcourt, Lise J and Ezekowitz, Justin and Fitzgerald, Mark and Gattas, David and Godoy, Lucas C and Goossens, Herman and Haniffa, Rashan and Harrison, David A and Hills, Thomas and Horvat, Christopher M and Ichihara, Nao and Lamontagne, Francois and Linstrum, Kelsey M and McAuley, Daniel F and McGlothlin, Anna and McGuinness, Shay P and McQuilten, Zoe and Murthy, Srinivas and Nichol, Alistair D},
  title = {Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2023.4480}
}
Kostenlos starten →